{
  "id": "mhgap#risk_safety_3f6d2e7e",
  "content": "(dropouts from treatment), duration of treatment\ny Further evidence is required to conclude whether\nlonger than 12 weeks showed effect, but no other\nthe balance of effects differs between baclofen and\ndifference was identified for adverse events or\nacamprosate or naltrexone.\ndropouts due to adverse events for dosages,\nduration of treatment or detoxification status.\nImplementation considerations\nRemarks y Baclofen is available in a generic form and is\ninexpensive but may not be available in all\ny The term “alcohol dependence” refers to diagnosis\ncountries and is not registered for the treatment\naccording to The ICD-10 classification of mental and\nof alcohol dependence. The lack of formal\nbehavioural disorders (26) or the Diagnostic and\napproval for baclofen’s use for alcohol dependence\nstatistical manual of mental disorders (27), 4th\nplaces increased responsibility on the medical\nedition (DSM-IV) criteria or equivalent ICD-11 (28)\npractitioner prescribing baclofen to inform\nand DSM-5 diagnosis (29).\n12\n3. Recommendations\npeople of the risks and benefits of its use for baclofen treatment can be associated with a\nalcohol dependence. mild benzodiazepine-like withdrawal syndrome.\ny Even though differences were not identified Therefore, baclofen should be reduced gradually",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "screening_cues",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety (dropouts from treatment), duration of treatment\ny Further evidence is required to conclude whether\nlonger than 12 weeks showed effect, but no other\nthe balance of effects differs between baclofen and\ndifference was identified for adverse events or\nacamprosate or naltrexone.\ndropouts due to adverse events for dosages,\nduration of treatment or detoxification status.\nImplementation considerations\nRemarks y Baclofen is available in a generic form and is\ninexpensive but may not be available in all\ny The term “alcohol dependence” refers to diagnosis\ncountries and is not registered for the treatment\naccording to The ICD-10 classification of mental and\nof alcohol dependence. The lack of formal\nbehavioural disorders (26) or the Diagnostic and\napproval for baclofen’s use for alcohol dependence\nstatistical manual of mental disorders (27), 4th\nplaces increased responsibility on the medical\nedition (DSM-IV) criteria or equivalent ICD-11 (28)\npractitioner prescribing baclofen to inform\nand DSM-5 diagnosis (29).\n12\n3. Recommendations\npeople of the risks and benefits of its use for baclofen treatment can be associated with a\nalcohol dependence. mild benzodiazepine-like withdrawal syndrome.\ny Even though differences were not identified Therefore, baclofen should be reduced gradually (dropouts from treatment), duration of treatment\ny further evidence is required to conclude whether\nlonger than 12 weeks showed effect, but no other\nthe balance of effects differs between baclofen and\ndifference was iden..."
}